Takeda's emerging markets man snaps up Brazil's Multilab, surveys India, MENA, Lat Am
This article was originally published in Scrip
"We have to do a better job in Middle East, Turkey and Africa areas, where we see a great potential, and also in other Latin American countries where we are not present today, like Peru, Ecuador, Uruguay, etc." So said Jostein Davidsen, head of emerging markets commercial operations at Takeda, speaking to Scrip following the announcement that the company is to pay around $270 million for Brazil's Multilab (scripintelligence.com, 25 May 2012).
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.